Atlas Trials

To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma

Clinical trial NCT05400876 · UNKNOWN

Trial details

NCT number
NCT05400876
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Relapsed/Refractory Lymphoma
Start date
2022-06-09
Primary completion
2023-05-01
Enrollment
92

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.